← All indications
Meningitis
Inflammation of the coverings of the brain and/or spinal cord, which consist of the PIA MATER; ARACHNOID; and DURA MATER. Infections (viral, bacterial, and fungal) are the most common causes of this condition, but subarachnoid hemorrhage (HEMORRHAGES, SUBARACHNOID), chemical irritation (chemical MENINGITIS), granulomatous conditions, neoplastic conditions (CARCINOMATOUS MENINGITIS), and other inflammatory conditions may produce this syndrome. (From Joynt, Clinical Neurology, 1994, Ch24, p6)
Subtype terms (6)
More specific conditions that are subtypes of Meningitis in the MeSH hierarchy.
- Arachnoiditis
3 drugs approved
- Meningitis, Aseptic
3 drugs approved
- Meningitis, Bacterial
19 drugs (13 approved, 6 experimental)
- Meningitis, Fungal
2 drugs approved
- Meningitis, Viral
1 drug approved
- Meningoencephalitis
3 drugs approved
Drugs by status
Approved for this indication (10)
Phase 4 trials (13)
- diphtheria, tetanus and whole cell pertussis vaccine
- meningococcal (groups A, C, Y, W) CRM197 conjugate vaccine
- pneumococcal 13-valent conjugate vaccine
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine
- menafrivac
- pneumococcal 7-valent conjugate vaccine
- gentamicin
- meningococcal (groups A, C, Y, W) tetanus toxoid conjugate vaccine
- haemophilus influenzae type b conjugate vaccine
- acellular pertussis vaccine (including diptheria and tetanus toxoids)
- monovalent group c meningococcal vaccine
- quadrivalent groups a, c, y, and w-135 meningococcal vaccine
- Bivalent group A and C meningococcal vaccine
Phase 3 trials (20)
- vitamin d3
- human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant
- sulfamethoxazole
- vancomycin
- multi-valent pneumococcal conjugate vaccine
- live attenuated varicella vaccine
- mpv-a
- mpv-acyw135
- 10-valent Pneumococcal Conjugate Vaccine
- zinc dichloride
- measles, mumps, and rubella vaccine
- trimethoprim
- vitamin a
- tetanus toxoid
- meningococcal (group B) vaccine
- gbs-nn/nn2
- nmcv-5
- Monovalent group A meningococcal vaccine
- Monovalent group C meningococcal vaccine
- Inactivated polio virus - Enhanced
Phase 2 trials (19)
- 23-valent pneumococcal polysaccharide vaccine
- linezolid
- ceftazidime
- ceftobiprole
- micafungin
- bovine colostrum
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- mgawn1
- hepatitis b vaccine (recombinant)
- rotavirus vaccine, live, oral, pentavalent
- serogroup b meningococcal vaccine
- bevacizumab
- fluconazole
- amphotericin b
- menabc
- polysaccharide diphtheria toxoid conjugate vaccine
- tamoxifen
- autologous hematopoietic stem cells
- contezolid
Phase 1 trials (8)
Organizations
Organization Involved with Phase 4 Indications (48)
- Chiron
- Sanofi
- Sanofi-Aventis
- Novartis
- GlaxoSmithKline
- Walvax Biotechnology Co., Ltd.
- Epicentre
- National Institute of Allergy and Infectious Diseases (NIAID)
- Public Health England
- Hospital Universitari de Bellvitge
- University of Pittsburgh
- Hebei University
- Boston University
- University of London
- Harvard University
- Hospital Mutua de Terrassa
- Johns Hopkins University
- Makerere University
- Mbarara University of Science and Technology
- Universidad Autonoma de Madrid
- Universidad Complutense de Madrid
- University of Liverpool
- University of Oslo
- University of Seville
- University of Cape Town
- Pacira Pharmaceuticals
- University of Minnesota
- Badalona Hospital Germans Trias i Pujol
- University of Malawi
- Hospital Universitario Virgen Macarena
- +18 more
Organization Involved with Phase 3 Indications (56)
- Gilead Sciences
- Merck
- Pfizer
- Baxalta
- Beijing Minhai Biotechnology Co., Ltd
- Hualan Biological Engineering, Inc.
- Institut Pasteur
- Serum Institute of India Pvt. Ltd.
- French National Agency for Research on AIDS and Viral Hepatitis
- Medical Research Council
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Institute of Neurological Disorders and Stroke (NINDS)
- World Health Organization
- Dr. D. Y. Patil Dental College & Hospital
- Hospital Avicenne
- Indian Council of Medical Research
- Osaka University
- Papua New Guinea Institute of Medical Research
- Radboud University
- Seth Gordhandas Sunderdas Medical College
- Stanford University
- University of Lisbon
- University of Bordeaux
- Far Eastern Memorial Hospital
- Fudan University
- Tel Aviv University
- University of Cambridge
- University of Utah
- All India Institute of Medical Sciences
- University of Indonesia
- +26 more
Organization Involved with Phase 2 Indications (44)
- Enzon
- Astellas
- Genentech
- Wyeth
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Chiesi
- JN-International Medical Corporation
- Matinas Biopharma, Inc
- MacroGenics
- Global Alliance for TB Drug Development
- PENTA Foundation
- National Institutes of Health (NIH)
- Addis Ababa University
- Armauer Hansen Research Institute, Ethiopia
- Bambino Gesù Hospital and Research Institute
- Centre Leon Berard
- Duke University
- Institut Bergonié
- Institut National de la Santé Et de la Recherche Médicale, France
- University of Rochester
- University of South Florida
- University of Southern California
- Vinmec International Hospital
- University of California, San Francisco
- University of Copenhagen
- Uppsala University
- Health Protection Agency, United Kingdom
- Chesapeake Research Group, LLC
- University of Toulouse
- IRC Clinics, Towson
- +14 more
Organization Involved with Phase 1 Indications (20)
- Schering-Plough
- AstraZeneca
- Alkermes
- Reata Pharmaceuticals, Inc.
- National Cancer Institute (NCI)
- United States Army
- Baylor University
- Brown University
- University of Washington
- Pediatric Brain Tumor Consortium
- University of Milan
- University of Bern
- Mayo Clinic
- Wenzhou Medical University
- Zhejiang University
- International Extranodal Lymphoma Study Group
- University Amedeo Avogadro
- Moorgreen Hospital, Southampton
- China National Biotec Group Co., Ltd
- Johnson and Johnson
Organization Involved with Other Experimental Indications (12)